The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Cystic Fibrosis: Advanced CFTR Modulator Therapy

Targeted small-molecule therapy correcting the underlying CFTR protein defect in cystic fibrosis

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Çocuk Sağlığı ve Hastalıkları department. Book Appointment →

What is Cystic Fibrosis: Advanced CFTR Modulator Therapy?

Cystic fibrosis (CF) is an autosomal recessive disease caused by mutations in the CFTR gene encoding a chloride channel; CFTR modulators address the molecular defect rather than only symptoms.

Potentiators (ivacaftor) increase channel opening of CFTR at the cell surface for gating mutations such as G551D.

Correctors (tezacaftor, elexacaftor) help misfolded CFTR (especially F508del) traffic to the cell surface; combined with potentiators, they form dual or triple therapy.

Elexacaftor/tezacaftor/ivacaftor (Trikafta) is approved for patients ≥6 years carrying at least one F508del mutation, covering ~90% of CF patients.

Symptoms

Pre-treatment: chronic productive cough, recurrent pulmonary exacerbations, sinopulmonary infections (Pseudomonas, Staphylococcus)
Pancreatic insufficiency (steatorrhea, fat-soluble vitamin deficiency, growth failure)
CF-related diabetes, distal intestinal obstruction syndrome, hepatic involvement
Salty-tasting skin, infertility (CBAVD in males), osteopenia
Post-treatment: marked improvement in FEV1, weight gain, sweat chloride decrease, fewer exacerbations

Risk Factors

Genotype determines responsiveness; non-F508del/non-gating mutations may not benefit
Drug interactions through CYP3A4 (avoid strong inducers/inhibitors)
Pediatric age ≥1-6 years depending on specific modulator approval
Pre-existing severe liver disease requires dose adjustment and monitoring
Cataracts (especially in pediatric patients on ivacaftor) — annual ophthalmologic exam recommended

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Apply for genotype-based modulator eligibility evaluation as soon as a CF diagnosis is confirmed
  • Re-evaluate any patient on modulator therapy with new respiratory symptoms — exacerbations still occur but are reduced
  • Seek immediate review for unexpected liver enzyme elevation, rash, or visual changes during modulator treatment
  • Schedule pre-conception counseling and modulator continuation discussion in pregnancy

Treatment Methods

01
Genotype testing to determine modulator eligibility (CFTR2 database for variant classification)
02
Triple combination elexacaftor/tezacaftor/ivacaftor for eligible patients ≥6 years; ivacaftor monotherapy for gating mutations from age 1 month
03
Continue baseline CF therapy: airway clearance, dornase alfa, hypertonic saline, inhaled antibiotics, pancreatic enzymes, fat-soluble vitamins
04
Monitor liver enzymes (baseline, every 3 months for first year, then annually), eye exams in children
05
Multidisciplinary CF center care, exercise, nutritional support, and psychosocial support remain essential alongside modulator therapy

Which Department to Visit?

You can visit our Çocuk Sağlığı ve Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Çocuk Sağlığı ve Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Newborn Care

Çocuk Sağlığı ve Hastalıkları

The newborn period is a critical phase that requires attentive care of the umbilical stump, temperature regulation, feeding, monitoring of jaundice and screening tests.

Vaccination Schedule

Çocuk Sağlığı ve Hastalıkları

The Turkish Ministry of Health national vaccination schedule arranges the immunization program from birth to adulthood. Timely and complete vaccination is critical in protecting community immunity.

Jaundice in Infants

Çocuk Sağlığı ve Hastalıkları

Neonatal jaundice (jaundice in newborns) presents as yellowing of the skin and eyes. The vast majority of cases are physiological and are easily treated with phototherapy.

Diarrhoea in Infants

Çocuk Sağlığı ve Hastalıkları

Acute diarrhoea is defined as 3 or more loose stools per day. In infants it is most often caused by viral gastroenteritis (rotavirus, norovirus); dehydration may lead to serious complications.

Fever Management in Children

Çocuk Sağlığı ve Hastalıkları

Fever in children (38°C and above) is the body's defense mechanism against viral or bacterial infection. Most fevers resolve spontaneously in 3-5 days; however, some conditions require urgent medical evaluation.

Cough in Children

Çocuk Sağlığı ve Hastalıkları

Cough is the most common symptom in children and is mostly due to viral upper respiratory infections. Cough lasting more than 3 weeks or with characteristic sounds requires detailed evaluation.

Bronchiolitis

Çocuk Sağlığı ve Hastalıkları

Supportive care with hydration, nasal suctioning, and oxygen if hypoxic is the mainstay; routine bronchodilators, corticosteroids, and antibiotics are not recommended per AAP/NICE guidelines.

Croup (Laryngotracheobronchitis)

Çocuk Sağlığı ve Hastalıkları

Croup is a viral inflammation of the larynx and trachea presenting with a barking cough, hoarseness, and inspiratory stridor. It mostly affects children aged 6 months to 3 years.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.